Earnings call transcripts

Earnings call transcripts with speakers and Q&A, usually within hours. Each one comes with a summary, the guidance management gave, and what analysts pressed on, free to read.

3,381 transcripts · 1,615 companiesHow to read a callBy API: the earnings call transcripts API.

Older calls

Page 282 of 282 · 3,381 calls

  • Lufax Holding (LU) Q4 2021 earnings call

    Management framed 2022 as a deliberate reset, prioritizing channel quality and transformation before expecting growth to resume in the second half.

    Date n/aMildly positive0.10
  • Natural Health Trends (NHTC) Q4 2021 earnings call

    Management framed the quarter as a volume-led recovery, while stressing that pandemic restrictions still constrain events and near-term visibility.

    Date n/aMildly positive0.25
  • Novo Nordisk A S (NVO) Q4 2021 earnings call

    Management framed 2022 as continued GLP-1-led growth, with obesity demand constrained by Wegovy supply and investment priorities weighing on margins. U.S.

    Date n/aPositive0.65
  • Shopify (SHOP) Q4 2021 earnings call

    Management framed 2022 around deepening merchant relationships and building capabilities, with fulfillment moving from experimentation into a more capital-intensive build phase.

    Date n/aPositive0.55
  • Staar Surgical (STAA) Q4 2021 earnings call

    Management framed 2022 as a capacity-building and brand-investment year, with non-U.S. markets leading growth while U.S. approval remains uncertain.

    Date n/aConfident0.72
  • Novo Nordisk A S (NVO) Q3 2021 earnings call

    Management framed results as broad-based, GLP-1-led growth, while stressing that 2021 was exceptional and that several temporary factors complicate 2022 comparisons.

    Date n/aConfident0.72
  • Shopify (SHOP) Q3 2021 earnings call

    Management framed normalization from pandemic e-commerce peaks as a return to steadier growth, while emphasizing broader omnichannel reach and merchant tools.

    Date n/aPositive0.55
  • Novo Nordisk A S (NVO) Q2 2021 earnings call

    Management framed the raised outlook as driven by obesity and GLP-1 momentum, while emphasizing launch investment and execution risks.

    Date n/aConfident0.70
  • Novo Nordisk A S (NVO) Q1 2021 earnings call

    Management framed the quarter as a strong start that lifted full-year expectations, while highlighting launch momentum and acknowledging pricing, competition, and COVID uncertainty.

    Date n/aConfident0.72

Companies covered

1,615 companies

152 more under A